Health policy making from the prospective of the European Community
Karen Kadenbach, Vienna, Austria

From costs of kidney disease to a healthier society
Raymond Vanholder, Ghent, Belgium



A network-oriented view of living systems to complement the reductionist
Andrew Kasarskis, New York, U.S.A.

Is it time for one-person trials?
Nicholas J. Schork, La Jolla, U.S.A.

Transplantation tolerance: can it turn into a reality?
Kathryn Wood, Oxford, United Kingdom


S 0.1
Tomorrow´s nephrology presented by the nephrologists of tomorrow (Young Nephrologists' Platform)
Update on YNP initiatives
Ana Carina Ferreira, Lisbon, Portugal

Can we achieve personalised medicine in ADPKD?

Emilie Cornec-Le Gall, Brest, France
Let´s talk about death! Regulated necrosis in acute kidney injury
Andreas Linkermann, Kiel, Germany
Immune monitoring in kidney transplant recipients
Oriol Bestard, Barcelona, Spain
Recent developments in atypical haemolytic uraemic syndrome
David Kavanagh, Newcastle Upon Tyne, United Kingdom

S 0.2
ERA-EDTA Registry
Lifetime risk of Renal Replacement Therapy in Europe
Jan Van Den Brand, Nijmegen, The Netherlands
Transplanting kidneys from older deceased donors: a comparison of outcomes in young and old recipients
Maria Pippias, Amsterdam, The Netherlands
Vascular access in children on hemodialysis
Michael Böhm, Vienna, Austria 
The effect of age on the prevalence of protein energy wasting among elderly Stage 4 CKD patients
Marie Evans, Stockholm, Sweden
Beta-blockers and outcomes in diabetic dialysis patients: data from EURODOPPS
Christiane Drechsler, Würzburg, Germany

S 0.3
Improving treatment of patients with CKD
Joint symposium ERA-EDTA & ISN
Strategies to increase the donor pool and access to transplantation
Rainer Oberbauer, Vienna, Austria
International guidelines: how relevant are they in developing countries?
Faiçal Jarraya, Sfax, Tunisia
Transplantation in HIV populations: lessons learned
Elmi Muller, Cape Town, South Africa
Variations in care and access to care
Adeera Levin, Vancouver, Canada

S 0.4
Joint symposium ERA-EDTA & ESC (European Society of Cardiology)
Cardiac function in CKD patients: how valuable are ECHO and biomarkers?
Carmine Zoccali, Reggio Calabria, Italy

Pathophysiology of hypertension in chronic kidney disease

Michel Burnier, Lausanne, Switzerland
Uncontrolled hypertension - how to prevent unfavourable kidney outcome?
Andrzej Wiecek, Katowice, Poland

How low should blood pressure be lowered to protect the kidney in chronic kidney disease
Josep Redon, Valencia, Spain

S 0.5
Joint symposium ERA-EDTA & ESH (European Society of Hypertension)
The kidney as a target of high blood pressure - the evidence in 2016
Johannes F.E. Mann, Munich, Germany
Renal angioplasty - is there still an indication in hypertensive CKD patients with RAS?
Patrick Rossignol, Vandoeuvre-Les-Nancy, France
Which future for the treatment of hypertension with renal denervation?

Roland E. Schmieder, Erlangen, Germany

Management of hypertension in patients with CKD

Michel Burnier, Lausanne, Switzerland


S 0.6
Joint symposium ERA-EDTA & ESPN (European Society for Paediatric Nephrology)
ADPKD: from Adult to Autosomal Dominant Polycystic Kidney Disease?
Ron T. Gansevoort, Groningen, The Netherlands

Management of cystic diseases from childhood to adulthood

Djalila Mekahli, Leuven, Belgium
KDIGO CKD-MBD Guideline Update 2016: Considerations in adults vs. children
Markus Ketteler, Coburg, Germany 
HDF - should this be the standard of care for children?
Rukshana Shroff, London, United Kingdom

S 0.7
Joint symposium ERA-EDTA & JSN (Japanese Society of Nephrology)
The mechanisms of AKI to CKD continuum
Motoko Yanagita, Kyoto, Japan
Outcome of CKD-MBD: pathophysiology and management
Masafumi Fukagawa, Isehara, Japan
Biomarkers of progressive renal disease - are we looking for the right ones?
Gert Mayer, Innsbruck, Austria
Lipoproteins and outcome in CKD - the other view
Danilo Fliser, Homburg/Saar, Germany

S 0.8
ASN Highlights

Glomerular Diseases

Brad Rovin, Columbus, U.S.A


John Friedewald, Chicago, U.S.A


Speaker to be confirmed


S 0.9
The Dialysis Outcomes and Practice Patterns Study (DOPPS) Program: Celebrating 20 Years and Looking Ahead
The DOPPS Program continues to grow and invites collaborators
Francesca Tentori, Ann Arbor, U.S.A.
Key lessons from the first 20 years of DOPPS
Michel Jadoul, Brussels, Belgium
Guideline adherence and drug prescription in EURODOPPS - Findings from the first proposal call
Sophie Liabeuf, Amiens, France
CKDopps: Improving outcomes in advanced CKD and the transition to dialysis
Ziad Massy, Paris, France
PDOPPS: the largest international study of PD practices
Simon Davies, Stoke-On-Trent, United Kingdom

S 0.10
Ethics in scientific research
Good scientific practice, sloppy science and research misconduct
Gerlinde Sponholz, Berlin, Germany
An ethical approach to the evidence-based development of clinical guidelines
Evi Nagler, Ghent, Belgium
Scientific journals and conflict of interest disclosure
Philippa Berman, London, United Kingdom
What is the impact of tightening animal rights on translational research: jumping from Petri dish to human?
Akos Koller, Budapest, Hungary

S 0.11
NDT Polar Views - Should we correct vitamin D deficiency/insufficiency in CKD patients with inactive forms of vitamin D or just treat them with active vitamin D forms?
David Goldsmith, London, United Kingdom
Rajiv Agarwal, Indianapolis, U.S.A.

S 0.12
Late Breaking Clinical Trials

S 0.13
The Lancet/The Lancet Diabetes and Endocrinology

S 0.15
Renal Replacement Therapy in Europe and in China (Joint symposium ERA-EDTA & CSN)
Transplantation data from Europe

Rainer Oberbauer, Vienna, Austria

European perspective of dyalysis based on the ERA-EDTA Registry data

Kitty Jager, Amsterdam, The Netherlands

CKD in China: current and perspective

Xueqing Yu, Guangzhou, China

Extracorporeal Therapies in critical care Nephrology: experience from China

Yongchun Ge, Nanjing, China


S 1.1
When cell biology meets tubular transport
mTOR and autophagy in tubular health and injury
Tobias Huber, Freiburg, Germany
The endolysosomal system in the proximal tubule
Olivier Devuyst, Zurich, Switzerland
Regulation of sodium channel trafficking
Olivier Staub, Lausanne, Switzerland
Cell biology of collecting duct water transport
Robert Fenton, Aarhus, Denmark

S 1.2
Sensing mechanisms in nephrology
Calcium-sensing in the kidney
Pascal Houillier, Paris, France
J. Mariano Rodriguez, Cordoba, Spain
Renal and extrarenal sensing of acid-base
Carsten Wagner, Zurich, Switzerland
David Ellison, Portland, U.S.A.

S 1.3
Hypoxia in kidney disease: integrating pre-clinical with clinical research
Oxygen sensing in the kidney
Volker H. Haase, Nashville, U.S.A.
Development of novel drugs targeting renal hypoxia and anaemia
Masaomi Nangaku, Tokyo, Japan
Imaging oxygen metabolism: Imaging oxygen metabolism: from animal and human studies
Christoffer Laustsen, Aarhus, Denmark
Using MRI to assess renal haemodynamics and oxygenation in humans
Susan Francis, Nottingham, United Kingdom

S 2.1
Actualities in hereditary disorders
ADPKD in children: new perspectives
Francesco Emma, Rome, Italy
Genetic testing for rare disorders: practical steps
Nine V.A.M. Knoers, Utrecht, The Netherlands
Inherited tubulopathies
Olivier Devuyst, Zurich, Switzerland
Ciliopathies and cystic disorders
Carsten Bergmann, Ingelheim Am Rhein, Germany

S 2.2
Dialysis and transplantation in children
Optimising BP control in CKD and dialysis patients
Fabio Paglialonga, Milan, Italy
What have we learnt from peritoneal membrane biopsies: bench to bedside
Claus Peter Schmitt, Heidelberg, Germany
CKD-MBD in children: is bone disease the heart of the problem?
Rukshana Shroff, London, United Kingdom
Corticosteroid-free kidney transplantation
Ryszard Grenda, Warsaw, Poland

S 2.3
Development and pregnancy
Dieter Haffner, Hannover, Germany 
Renal progenitor cells to model inherited disorders
Paola Romagnani, Florence, Italy
Immunisation in pregnancy leads to membranous nephropathy
Pierre Ronco, Paris, France
Pathophysiology of pre-eclampsia
Matthew Hall, Nottingham, United Kingdom

S 3.1
Kidney in systemic inflammatory diseases
B cell cytokine blockade in SLE
David Jayne, Cambridge, United Kingdom
New and old auto-antibodies for lupus nephritis
Gian Marco Ghiggeri, Genoa, Italy
Biologic drugs in the treatment of vasculitis
Vladimir Tesar, Prague, Czech Republic
New ways to interfere with the complement system
Giuseppe Remuzzi, Bergamo, Italy

S 3.2
What precipitates IgAN and what is the target for treatment?
Genetic determination in IgA Nephropathy
Krzysztof Kiryluk, New York, U.S.A.
The intestine-renal connection
Rosanna Coppo, Turin, Italy
Shall we treat intestinal immunity only?
Bengt Fellström, Uppsala, Sweden
Shall we treat the systemic inflammation? Lessons from STOP IgAN
Jürgen Floege, Aachen, Germany

S 3.3
Renal fibrosis: new insights
Perivascular progenitors, Hedgehog signaling and kidney fibrosis
Rafael Kramann, Aachen, Germany
The role of microvascular endothelium in progressive kidney disease
Bernd Hohenstein, Dresden, Germany
New mediators of renal fibrosis, or the road to therapy
Christos Chatziantoniou, Paris, France
Established mediators of renal fibrosis – where are the clinical trials?
Roel Goldschmeding, Utrecht, The Netherlands

S 3.4
Membranous nephropathy: new insights
The pathogenetic and clinical role of glomerular antigens in membranous nephropathy
Rolf A.K. Stahl, Hamburg, Germany
The PLA2R autoantigen: from pathophysiology to patients' care
Pierre Ronco, Paris, France
Calcineurin inhibitors in membranous nephropathy
Manuel Praga, Madrid, Spain
Rituximab in membranous nephropathy
Piero Ruggenenti, Bergamo, Italy

S 3.5
Immunology and the kidney
NETs, histones and necroinflammation in kidney disease
Hans-Joachim Anders, Munich, Germany
T cells in glomerulonephritis
Kathrin Eller, Graz, Austria
Kidney dendritic cells in acute and chronic renal disease
Christian Kurts, Bonn, Germany
Intracellular signals as druggable targets in renal inflammation
Jesus Egido, Madrid, Spain

S 3.6
The gut-renal axis
The gut microbiome in health and CKD
Pieter Evenepoel, Leuven, Belgium
Targeting gut-derived uremic toxins
Timothy Meyer, Palo Alto, U.S.A.
The nasal microbiome in granulomatosis with polyangiitis (GPA, Wegener's)
Andreas Kronbichler, Innsbruck, Austria
IgAn and microbiota
Loreto Gesualdo, Bari, Italy

S 4.1
Lingering questions in CKD
Is early nephrology care so important in stage 3b-4 CKD patients?
Goce Spasovski, Skopje, F.Y.R. of Macedonia
Is sleep apnea a really major problem in CKD? Hypotheses and observations
Sydney Tang, Hong Kong, Hong Kong, P.R. China
Pulmonary hypertension in CKD patients: Relevant? Preventable? Treatable? 
Davide Bolignano, Reggio Calabria, Italy
Directly acting anti-HCV agents: ready for use in CKD/ESRD?

Michel Jadoul, Brussels, Belgium



S 4.2
Management of the frail and elderly with CKD
Nutritional status: evaluation and improvement
Denis Fouque, Lyon, France
Should dialysis be different in the frail elderly?
Olof Heimbürger, Stockholm, Sweden
Withholding and withdrawal of dialysis: models of care
Jacques Bernheim, Tel Aviv, Israel
Models for prediction of need for RRT vs risk of death in the elderly
Evi Nagler, Ghent, Belgium

S 4.3
Aging and CKD
EVA & ADAM: impact on aging kidneys
Alberto Ortiz, Madrid, Spain
BOLD MRI: a key measure to diagnose ischemic nephropathy
Menno Pruijm, Lausanne, Switzerland
Aortic aging in ESRD: structural, hemodynamic and mortality implications
Gérard London, Paris, France
New markers of frailty: myostatin
Thomas Bernd Dschietzig, Bensheim, Germany

S 4.4
Gone with the Wnt
Wnt signaling in vascular caldification
Mario Cozzolino, Milan, Italy
Wnt signaling in bone diseases
Martine Cohen-Solal, Paris, France
Limitations of the current therapies for osteoporosis in patients with CKD
Susan M. Ott, Seattle, U.S.A.
Sclerostin and the CV System
Vincent Brandenburg, Aachen, Germany

S 4.5
New aspects of sex hormones abnormalities in CKD patients
Testosterone deficiency - why it is important in male CKD patients
Mahmut Ilker Yilmaz, Ankara, Turkey
Hyperprolactinemia in CKD patients - friend or foe
Juan Jesus Carrero, Stockholm, Sweden
Female infertility in CKD and antimϋllerian hormone
Marcin Adamczak, Katowice, Poland
Sexuality after successful kidney transplantation
Uwe Heemann, Munich, Germany

S 4.6
Novel oral anticoagulants or warfarin in CKD?
Is chronic anticoagulation treatment needed in chronic kidney disease?
Adrian Covic, Iasi, Romania
Do novel oral anticoagulants differ from vitamin K antagonists for efficacy or bleeding?
Jürgen Floege, Aachen, Germany
Stroke and bleeding in atrial fibrillation with chronic kidney disease
Anne Lise Kamper, Copenhagen, Denmark
Novel oral anticoagulants or warfarin in CKD ‐ a cardiologists perspective
Karolina Szummer, Stockholm, Sweden

S 4.7
Lipids in nephrology
Lipoproteins in Nephrology: clinical importance and therapeutic options
Kurt Derfler, Vienna, Austria 
Lipid homeostasis in CKD: Focus on HDL cholesterol
Marcus, Säemann, Vienna, Austria
Lipid lowering in CKD: yes, no, maybe
Christoph Wanner, Würzburg, Germany
Lipids and CKD progression: myth or reality?
Alexander Rosenkranz, Graz, Austria

S 4.8
Bone, calcium and PTH in CKD
The rapidly exchangeable calcium pool in hemodialysis patients
Markus Pirklbauer, Innsbruck, Austria
Clinical evaluation of bone: what makes sense?
Daniel Cejka, Vienna, Austria
What prophylaxis and therapy is really useful?
Sylvie Dusilova Sulkova, Hradec Kralove, Czech Republic
Uremic toxins and CKD-MBD
Ziad Massy, Paris, France

S 5.1
Vascular access for HD
Pre-operative evaluation of vascular capital

Pedro Ponce, Maria Guedes Marques, Portugal

Predictors of fistula function
Marko Malovrh, Radomlje, Slovenia
Non-pharmaceutical and pharmaceutical strategies to enhance fistula maturation and primary patency
Jan H. M. Tordoir, Maastricht, The Netherlands
Lock solutions to prevent clothing and infection in tunneled dialysis catheters
Laura Labriola, Brussels, Belgium

S 5.2
Nutrition in CKD patients
Metabolic and clinical rationale for enteral support
Denis Fouque, Lyon, France
Clinical trials update in CKD patients (including HD)
Wilfred Druml, Vienna, Austria
Should enteral support be identical in HD and PD?
Pieter M. Ter Wee, Amsterdam, The Netherlands
Low calorie diet in obese patients with CKD
Fitsum Guebre-Egziabher, Grenoble, France

S 5.3
Calcification and calciphylaxis
Calcification in heart valves: clinical implications, consequences, therapy
Pablo Antonio Ureña Torres, Saint-Ouen, France 
Vascular calcification in CKD patients: evaluation and outcomes
Teresa Adragao, Cascais, Portugal
New insights into the FGF23-Klotho axis
Hannes Olauson, Cambridge, U.S.A
Uraemic calciphylaxis - clinical picture, course and therapeutic options
Markus Ketteler, Coburg, Germany

S 5.4
Personalized dialysis
Frequent or longer hemodialysis - benefits more than risks?
Pantelis A. Sarafidis, Thessaloniki, Greece
Dialysis modality choice in diabetic patients with end-stage kidney disease
Davide Bolignano, Reggio Calabria, Italy
Dialysis modalities and interventions to reduce intra-dialytic symptoms
Andrew Davenport, London, United Kingdom
Is online HDF the new standard for extracorporeal therapy?
Francesco Locatelli, Lecco, Italy

S 5.5
Whole person care in Nephrology
Uremic pruritus and xerosis
Jacek C. Szepietowski, Wroclaw, Poland

The future impact of schistosomal nephropathies

Rashad Barsoum, Cairo, Egypt
Fatigue in haemodialysis patients
Maurizio Bossola, Rome, Italy
Psychological care of patients with CKD: Opportunities for relationship-centered care
Marta Novak, Toronto, Canada

S 6.1
PD clinical science
Bio-impedance: coming of age?
Jeroen Kooman, Maastricht, The Netherlands
Transition between modalities: what do we (not yet) know?
Christopher T. Chan, Toronto, Canada
Management of infections in PD
Anabela Rodrigues, Porto, Portugal 
Peritoneal dialysis cather insertion and continuous access care: interdisciplinary challenges and pre-emptive practices
Catalin Buga, Bucharest, Romania

S 6.2
Should PD as initial dialysis modality become the standard of care?
CKDopps: Optimal timing of dialysis initiation and modality selection
Roberto Pecoits-Filho, Curitiba, Brazil
Urgent Start of PD: PD First as standard of care?
James Heaf, Copenhagen, Denmark
How can residual renal function be preserved?
Sylvie Opatrná, Senec, Czech Republic
PDopps: Optimizing PD and reducing technique failure rate
Simon Davies, Stoke-On-Trent, United Kingdom

S 6.3
Quality Improvement in PD
organised in collaboration with International Society of Peritoneal Dialysis (ISPD)
Updates on ISPD Peritoneal Dialysis Infection Guidelines
Philip Li, Hong Kong, Hong Kong, P.R. China
Integrating geriatric care for older patients on PD
Edwina Brown, London, United Kingdom
ISPD Cardiovascular and Metabolic Guidelines
Rajnish Mehrotra, Seattle, U.S.A.

S 7.1
Improving cardiovascular risk assessment in transplant patients
Metabolic risk factor profile before and after renal transplantation
Adnan Sharif, Birmingham, United Kingdom
Non-invasive cardiac imaging in the evaluation of kidney transplant candidates
Alan, Jardine, Glasgow, United Kingdom
24h-ABPM in renal transplant patients: the nocturnal BP burden
Francesca Mallamaci, Reggio Calabria, Italy
How to approach post-transplant diabetes?
Marcus Säemann, Vienna, Austria

S 7.2
The living kidney donor
Development of CVD risk factors shortly after donation
Alaattin Yildiz, Istanbul, Turkey
The Oslo experience: long term risk after donation
Geir Mjøen, Oslo, Norway
Practice patterns for follow up of the kidney donors
Bruno Watschinger, Vienna, Austria
Psychological outcomes after living kidney donation
Hannah Maple, London, United Kingdom

S 7.3
Lingering issues in kidney transplantation
Pre-emptive kidney re-transplantation - If yes, when and for whom?
Maria Alicja Debska-Slizien, Gdansk, Poland
Immune surveillance after kidney transplantation
Martina Sester, Homburg/Saar, Germany
How to diminish the long-term renal allograft loss?
Marian Klinger, Wroclaw, Poland

S 7.4
How to handle the sensitized kidney transplant recipient
Precision diagnosis and risk stratification in kidney transplantation
Alexandre Loupy, Paris, France
Desensitization protocols: is there a favorite?
Georg A. Böhmig, Vienna, Austria
Treatment of ABMR: when to treat and what tools do we have?
Søren Schwartz Sørensen, Copenhagen, Denmark
Paired kidney donation
Ondrej Viklicky, Prague, Czech Republic

S 7.5
DGF: how to prevent it?
Intrarenal molecular events after death
Alberto Ortiz, Madrid, Spain
Integrational aspects of DGF - towards a rational treatment
Rainer Oberbauer, Vienna, Austria
Machine perfusion to preserve or to resuscitate: where are we today?
Ina Jochmans, Leuven, Belgium
Ischemic pre-conditioning in kidney transplantation outcomes: is time for a trial?
Daniel Abramowicz, Brussels, Belgium

S 8.1
Salt on the table
Salt consumption and cardiovascular disease: from etiology to prevention
Francesco Paolo Cappuccio, Coventry, United Kingdom
Salt consumption and renal outcomes
Johannes F.E. Mann, Munich, Germany
Dialysate sodium: friend or foe?
Mustafa Arici, Ankara, Turkey

S 8.2
Uremic cardiomyopathy
Thick but weak: the pathophysiology of uremic cardiomyopathy
Kerstin Amann, Erlangen, Germany
Non-invasive assessment of cardiac structure and function - what nephrologists must know
Frank Flachskampf, Uppsala, Sweden
Clinical consequences: cardiac arrhythmia and SCD
Philip A. Kalra, Salford, United Kingdom
Future perspectives in the treatment of uremic cardiomyopathy
Marc Vervloet, Amsterdam, The Netherlands

S 8.4
Obesity and fat tissue – what is new and what is relevant for nephrologists?
New classification of obesity – not only BMI
Bernhard Ludvik, Vienna, Austria
Obesity - a disease with many aetiologies disguised in the same oversized phenotype
Peter Stenvinkel, Stockholm, Sweden
Metabolic syndrome and renal outcome - a reappraisal
Andrzej J. Wiecek, Katowice, Poland
Renal consequences of bariatric surgery - the downsides
Allon Friedman, Carmel, U.S.A.

S 9.1
Cross-talk between kidneys and other organs in AKI
AKI and the heart
Claudio Ronco, Vicenza, Italy
AKI and the lung
Carmine Zoccali, Reggio Calabria, Italy
Novel evidence on the treatment of hepatorenal syndrome
Fabrizio Fabrizi, Milan, Italy
AKI in pregnancy
Fadi Fakhouri, Nantes, France

S 9.2
AKI - pathophysiology and definition
Biomarkers as a tool to understand pathophysiology of AKI
Jill Vanmassenhove, Ghent, Belgium
Looking through RIFLE, AKIN and KDIGO glasses: do we see the same?
Marlies Ostermann, London, United Kingdom
Acute intestitial nephritis: an overlooked cause of AKI?
Manuel Praga, Madrid, Spain
CKD imposed on AKI and vice versa
Mehmet Sukru Sever, Istanbul, Turkey

S 9.3
Fluid management in the ICU
Prevent the kidneys from drowning - How to assess fluid status in ICU patients
Jan T. Kielstein, Braunschweig, Germany
How to manage fluids in pediatric ICU patients?
Johan Vande Walle, Ghent, Belgium
In whom when which type of fluid: state of the art
Can Ince, Rotterdam, The Netherlands
Fluid overload at cardiac ICU: diuretics, slow ultrafiltration or peritoneal dialysis?
Jeroen Kooman, Maastricht, The Netherlands

S 9.4
Special technological aspects of ICU nephrology and extracorporeal treatment
CO2 removal: indications, outcomes, technology
Eric Hoste, Ghent, Belgium
Liver dialysis: technology, indications, outcomes
Achim Joerres, Berlin, Germany
ICU dialysis in the paediatric setting: outcomes and technological considerations
Franz Schaefer, Heidelberg, Germany
Extracorporeal treatment of immune mediated kidney disease
George Reusz, Budapest, Hungary

S 9.5
Special situations with need for nephrology advice
Prevention and management of AKI in the general ward: the UK experience
Nicholas Selby, Derby, United Kingdom
How and when (not) to dialyse the frail and elderly with AKI
Wim Van Biesen, Ghent, Belgium
Pharmacokinetics of drugs in AKI and during RRT: what we should know?
Jan T. Kielstein, Braunschweig, Germany



Managing PD patients - from basic principles to advanced practice
PD catheter: life line or strangling device?
Martin Wilkie, Sheffield, United Kingdom
Adequate PD prescription: balancing different interests
Simon Davies, Stoke-On-Trent, United Kingdom


CME 01 - IWG

News in the diagnostics and treatment of glomerular disease

Critical review of renal biopsy

Indications for renal biopsy: when it is needed?
Loreto Gesualdo, Bari, Italy
Evidence based classification of renal pathology
Ian Roberts, Oxford, United Kingdom
Can biomarkers substitute renal biopsy in IgA nephropathy?
Yasar Caliskan, Istanbul, Turkey
What is the added value of renal biopsy and rebiopsy to clinical data in lupus
Gabriella Moroni, Pavia, Italy
What is the added value of renal biopsy to clinical data in vasculitis
Ingeborg M. Bajema, Leiden, The Netherlands

4 years after the KDIGO guidelines on glomerular diseases: when to update them?

Membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
IgA nephropathy
Jürgen Floege, Aachen, Germany
FSGS/minimal change disease
Rosanna Coppo, Turin, Italy
Lupus nephritis
David Jayne, Cambridge, United Kingdom
ANCA-associated vasculitis
Vladimir Tesar, Prague, Czech Republic



Practical issues in kidney transplantation

Indications and complications of bariatric surgery before and after transplantation
Franco Citterio, Rome, Italy
Transplantation into an abnormal lower urinary tract: what should the nephrologist know?
Licia Peruzzi, Turin, Italy
Thrombotic microangiopathy in kidney allograft - how to proceed?
Christophe Legendre, Paris, France
Risk scores in kidney transplantation: how useful are they?
Marc Hazzan, Lille, France
How to avoid DGF: patient perfusion or machine kidney perfusion?
Rainer Oberbauer, Vienna, Austria
How can you improve the outcomes of your kidney transplant program?
Daniel Abramowicz, Brussels, Belgium
Assessment of recipient alloreactivity before transplantation
Ondrej Viklicky, Prague, Czech Republic
Should we treat asymptomatic bacteriuria after renal transplantation?
Julien Coussement, Brussels, Belgium



A preview of the future in cardiovascular risk management in CKD

Uremic toxins, genetics and systemic disorders at the kidney-cardiovascular system interface

Future pathways to decrease concentration of cardiotoxic uremic toxins
Raymond Vanholder, Ghent, Belgium
Genetic epidemiology of the cardio-renal risk linked to urate transporters
Francesca Mallamaci, Reggio Calabria, Italy
Hypertension in systemic diseases
Andrzej J. Wiecek, Katowice, Poland

Decreasing adverse cardiac outcomes in CKD

Renal congestion in heart failure: concept and impact on outcome
Mehmet Kanbay, Istanbul, Turkey
Novel therapeutic approaches to heart failure in CKD patients
Patrick Rossignol, Vandoeuvre-Les-Nancy, France
How to prevent sudden death in chronic kidney disease
Gunnar Heine, Homburg/Saar, Germany



Hemodiafiltration - the new standard of care?

How to dose dialysis therapy: paradigm shift from urea to volume

Why should higher volume on-line haemodiafiltration improve survival?
Carlo Basile, Acquaviva delle Fonti, Italy
Hydration status and survival in haemodialysis patients
Andrew Davenport, London, United Kingdom
Does achieving bioimpedance guided normovolaemia increase intradialytic hypotension and loss of residual renal function?
Frank M. Van Der Sande, Maastricht, The Netherlands

Recent trials in HDF

Clinical evidence on HDF
Peter J. Blankestijn, Utrecht, The Netherlands
Incremental dialysis - does less dialysis preserve residual renal function?
Enric Vilar, Stevenage, United Kingdom
HDF around the globe: acceptance and regulatory issues worldwide
Bernard Canaud, Montpellier, France
Achieving more frequent and longer dialysis: compelling evidence from clinical trials?
Sandip Mitra, Manchester, United Kingdom



Diabetes and obesity in renal disease

The effect of weight loss in obesity and chronic kidney disease
Enrique Morales, Madrid, Spain
Renal lipotoxicity: evidence of lipid deposits in human kidneys
Esteban Porrini, La Laguna, Spain
Glycemic control in patients with kidney disease: how to individualize the treatment
Drazenka Pongrac Barlovic, Ljubljana, Slovenia
NAFLD and microalbuminuria in the Netherlands Epidemiology of Obesity Study
Aiko De Vries, Leiden, The Netherlands
Macrophages and diabetic kidney disease
Josep Cruzado, Barcelona, Spain
The role of glomerular hyperfiltration in renal disease in obesity and diabetes
Avry Chagnac, Petah Tikva, Israel



As we grow old - nutritional considerations for the CKD elderly patient

The growing population of elderly dialysis patients: prevalence and consequences of protein-energy wasting
Siren Sezer, Ankara, Turkey
Diagnosing protein-energy wasting in the elderly dialysis patient: Should it be any different from younger patients?
Lina Johansson, London, United Kingdom
Nutritional requirements and nutritional management of elderly dialysis patients: should it be any different from younger patients?
Daniel Teta, Sion, Switzerland
Sarcopenia and frailty in the elderly dialysis patient: concepts of clinical applicability or just theoretical artifacts?
Juan Jesus Carrero, Stockholm, Sweden
Physical activity in the elderly dialysis patient
Anne Kolko-Labadens, Suresnes, France
Treating the whole patient: Emphasizing quality of life
Vincenzo Bellizzi, Salerno, Italy
Dialysis technique choice for the elderly dialysis patient: impact on nutritional status
Pieter M. Ter Wee, Amsterdam, The Netherlands


CME 07 – EUTox WG

Uraemia: is it only a toxin affair? The emerging concept of networking

The cell response to uraemic toxins

Uraemia and endothelial cells
Stéphane Burtey, Marseille, France
The renal tubular handling of uremic metabolites
Rosalinde Masereeuw, Utrecht, The Netherlands
Uraemia and blood cells
Griet Glorieux, Ghent, Belgium

CKD modification of the agonists and receptors: the integrative view of uraemic toxicity

Post translational modifications of the agonists in CKD
Vera Jankowski, Aachen, Germany
Receptors and altered target organs response in CKD
J. Mariano Rodriguez, Cordoba, Spain
The emergence of networking concept in uraemic toxicity: the integrative view
Alberto Ortiz, Madrid, Spain



Inherited Disorders: the kidney and beyond

Mitochondrial disorders
Francesco Emma, Rome, Italy
Intellectual disability and kidney disease
Nine V.A.M. Knoers, Utrecht, The Netherlands
Guidance and consensus reports on Fabry disease
Roser Torra, Barcelona, Spain
When the kidney biopsy speaks
Renate Kain, Vienna, Austria
News from the Impulsions Grants: Role of endolysosomes and autophagy in Dent disease
Alessandro Luciani, Zurich, Switzerland
News from the Impulsion Grants: Identification and functional characterization of new magnesiotropic genes
Francisco J. Arjona Madueno, Nijmegen, The Netherlands
News from the WGIKD
Olivier Devuyst, Zurich, Switzerland


CME 09

Rheumatology for nephrologists

Management of RA patients with CKD

Volker Vielhauer, Munich, Germany

Gout management in CKD
Hans-Joachim Anders, Munich, Germany

Kidney manifestations in Primary Sjögrens Syndrome
Dana Kidder, Aberdeen, United Kingdom
Scleroderma – an update for nephrologists
Ariane Herrick, Manchester, United Kingdom
My lupus nephritis patient has persistent proteinuria - what to do?
David Jayne, Cambridge, United Kingdom
The topoisomerase I inhibitor irinotecan as a new treatment option for lupus nephritis?

Steffen Frese, Berlin, Germany



New insights into CKD-MBD

Old and new biomarkers in CKD-MBD

Will Klotho and FGF23 make you change your clinical practice?
Marc Vervloet, Amsterdam, The Netherlands
Alkaline phosphatase
Jordi Bover, Barcelona, Spain
Mario Cozzolino, Milan, Italy

Too high, too low, defining the optimal PTH level in CKD

What do observational and intervention studies teach us?
David Goldsmith, London, United Kingdom
PTH resistance in CKD
Pieter Evenepoel, Leuven, Belgium
What is the role of bone biopsy and bone biomarkers?
Pablo Antonio Ureña Torres, Saint-Ouen, France


CME 11 - EuroPD

Peritoneal dialysis in 2016 - where do we stand?

Peritoneal membrane physiology and anatomy in 2016
Bert Bammens, Leuven, Belgium
Writing a suitable PD prescription in 2016
Monika Lichodziejewska-Niemierko, Gdańsk, Poland
Understanding infection in PD
Andreas Vychytil, Vienna, Austria
Nutrition in PD patients: still a cause of concern in 2016?
Juan Jesus Carrero, Stockholm, Sweden
Survival on PD - trends until 2016?
Moniek Van De Luijtgaarden, Amsterdam, The Netherlands
Keeping the patient euvolemic
Simon Davies, Stoke-On-Trent, United Kingdom
Home HD: Do's and dont's and underlying rationale
Wim Van Biesen, Ghent, Belgium


CME 12 

Disasters and the Nephrologist

The conceptual evolution of renal disasters
Garabed Eknoyan, Houston, U.S.A.
Renal Disaster Relief Task Force – Why was it founded? What did it achieve?
Norbert H. Lameire, Ghent, Belgium
Kidney problems in disasters other than earthquakes
Raymond Vanholder, Ghent, Belgium
Lessons learned from past disasters
Mehmet Sukru Sever, Istanbul, Turkey


CME 13

Amyloidosis – old problem, new issues

Amyloidosis - not so rare but underappreciated problem in nephrology
Jolanta Malyszko, Bialystok, Poland
New types of amyloidosis in their clinical relevance
Romana Rysava, Prague, Czech Republic
Diagnosis of amyloidosis – the easy and the not so easy diagnosis
Sanjeev Sethi, Rochester, U.S.A.
Promising new treatments of amyloidosis
Helen Lachmann, London, United Kingdom


CME 14

Including the patient perspective in renal care

Understanding quality of life in older people with CKD
Casper Franssen, Groningen, The Netherlands
Insights into the illness perceptions of older people with late CKD
Friedo W. Dekker, Leiden, The Netherlands
Using patient-reported outcomes in the clinic: lessons from other specialties
Sabine Van Der Veer, Manchester, United Kingdom
Routine collection of data on the patient perspective in renal registries: a European perspective
Fergus Caskey, Bristol, United Kingdom


CME 15

Transplantation immunology - an update

Update on donor cell specific antibodies
Christophe Legendre, Paris, France
Recurrent and de novo glomerulonephritis after transplantation
Claudio Ponticelli, Milan, Italy
Transplant glomerulopathy
Miklos Zsolt Molnar, Memphis, U.S.A.
Progress in transplantation tolerance
Ondrej Viklicky, Prague, Czech Republic
Novel immunosuppressives
Josep M. Grinyó, Barcelona, Spain


CME 16
In collaboration with EURORECKD

Prescription for health – Exercise as part of nephrological care

Learning from the EXCITE study

Carmine Zoccali, Reggio Calabria, Italy

Exercise as Medicine in CKD – experiences over 30 years

Naomi Clyne, Lund, Sweden

Exercise with dialysis patients – benefits for cardio-vascular health

Evangelia Kouidi, Thessaloniki, Greece

Benefits and challenges of exercise rehabilitation for kidney transplant recipients

Tom Mercer, Edinburgh, United Kingdom

Exercise prescription for health: Recommendation with reference to chronic kidney disease

Herbert Löllgen, Remscheid, Germany


CME 17

Non-pharmacological treatment of resistant hypertension - consensus for 2016

Selecting patients for renal denervation

Peter Blankestijn, Utrecht, The Netherlands

Baroreceptor activation: still an option?

Jan Menne, Hannover, Germany

Renal revascularization in high risk patients with RAS

Philip Kalra, Salford, United Kingdom

Central arteriovenous anastomosis

Roland E. Schmieder, Erlangen, Germany


CME 18

Less is more: why 'treating to targets' does not outcome of CKD patients?

Rise and fall of Hb target in CKD: from 'high normal' to 'just avoid transfusion'?

Francesco Locatelli, Lecco, Italy

Treatment of cardiovascular disease in CKD: does it really help?

Tomasz Stompor, Olsztyn, Poland

Treatment of CKD-MBD and outcome: any good news since KDIGO 2009?

Markus Ketteler, Coburg, Germany

Controversies in dialysis: when to start

Jonathan Fox, Glasgow, United Kingdom


CME 19

Nephrolithiasis and CKD (EULIS)

Risk of CKD in stone patients: the epidemiology perspective

Pietro Manuel Ferraro, Rome, Italy

The renal damage by urological treatments

Alberto Trinchieri, Lecco, Italy

Struvite stones: difficult to treat, difficult to prevent

Giovanni Gambaro, Rome, Italy

Christian Türk, Vienna, Austria

Nephrolithiasis and PDK (with an embedded clinical case)

Dominique Chauveau, Toulouse, France


CME 20

Crosstalk in renal epidemiology (ERA-EDTA Registry)

Transitional research in nephrology - Public Health

Simon Fraser, South Hampton, United Kingdom

Chances and challenges of using routine data collections for renal health care research

Gert Mayer, Vienna, Austria

Prediction models

Benedicte Stengel, Villejuif, France

The credibility of subgroup analysis

Georg Heinze, Vienna, Austria

Choosing the correct competing risk method - not always straightforward

Vianda Stel, Amsterdam, The Netherlands

STROBE and the quality of reporting observational studies in nephrology

Fergus Caskey, Bristol, United Kingdom


CME 21

Toxicology for nephrologists

Overview of elimination enhancement techniques in poisoning

Speaker to be confirmed

Summary of available extracorporeal treatment in poisoning

Jan Kielstein, Braunschweig, Germany

EXTRIP guidelines for extracorporeal removal of toxins: methodology and recommendations

Marc Ghannoum, Montreal, Canada

Presentation of the EXTRIP process to a new toxin (Dabigatran)

Robert Mactier, Glasgow, United Kingdom



The endothelial surface layer and the development of glomerular disease
Ton J. Rabelink, Leiden, The Netherlands


Fundamental mechanisms of osmosis - revisited
Johann Morelle, Brussels, Belgium


Inflammation, immunity and hypertension
Ulrich O. Wenzel, Hamburg, Germany


How to improve HD outcome in children: more convection, more time, more sessions?
Michel Fischbach, Strasbourg, France


Role of stem cells in kidney regeneration
Michal Chmielewski, Gdansk, Poland


Genetic testing in Steroid Resistant Nephrotic Syndrome

Moin Saleem, Bristol, United Kingdom


The value of kidney biopsy for the choice of therapy in patients with chronic GN
Loreto Gesualdo, Bari, Italy


Anti PLA2R antibodies and outcome of membranous nephropathy
Elion Hoxha, Hamburg, Germany


Guidelines in nephrology: what was expected? What was achieved?
Garabed Eknoyan, Houston, U.S.A.


Potential anti-ageing interventions in CKD
Peter Stenvinkel, Stockholm, Sweden


Blood pressure management in patients with CKD
Ivan Rychlik, Prague, Czech Republic


Vitamin D for better survival in CKD - any evidence?
David Goldsmith, London, United Kingdom


Uremic toxins - how far did we come in 2016?
Angel Argiles Ciscart, Montpellier, France


How valid are surrogate endpoints in nephrology research?
Carmine Zoccali, Reggio Calabria, Italy


Cardiovascular complications in CKD patients - what we have learned during the last 10 years?
Petar Kes, Zagreb, Croatia


How to prescribe Metformin in CKD
Marc E. De Broe, Lokeren, Belgium


Interventions to reduce progression of CKD - what is the evidence?
John Feehally, Leicester, United Kingdom


The emerging role for bone alkaline phosphatase isoforms in chronic kidney disease - mineral and bone disorder
Mathias Haarhaus, Stockholm, Sweden


Does calcium dialysate matter?
Ercan Ok, Izmir, Turkey


Haemodynamic modifications induced by dialysis vascular access
Carlo Basile, Acquaviva delle Fonti, Italy


New options for dialysis in neonates

Claudio Ronco, Vicenza, Italy


Peritoneal dialysis - what is new in 2016?
Monika Lichodziejewska-Niemierko, Gdańsk, Poland


Mesenchymal stem cells as a potential pretransplant desensitization tool
Gamal Saadi, Cairo, Egypt


Challenges of transplant rejection diagnosis
Kerstin Amann, Erlangen, Germany


Blood pressure variability and the kidney
Mustafa Arici, Ankara, Turkey


Clinical studies that target inflammation in diabetic nephropathy
Peter Rossing, Gentofte, Denmark


Pathogenesis and treatment of HFPEF in CKD

Loek Van Heerebeek, Amsterdam, The Netherlands


Management of hyponatremia - what do the guidelines say?
Goce Spasovski, Skopje, F.Y.R. of Macedonia


Antonino D'Antona and the first description in 1909 of the crush syndrome with renal failure after the Messina earthquake
Natale Gaspare De Santo, Naples, Italy